Please note that a publication can be assigned to several endpoints, i.e. the sum of publications from the individual thematic points and subpoints can be greater than the total sum of actual publications.
Authors | Year | Exposed system | Parameters | Magnetic flux density/field strength |
---|---|---|---|---|
Martínez MA et al. | 2019 | intact cell/cell culture, NB69 cells (human neuroblastoma cells) | 50/60 Hz, magnetic field | 100 µT |
McFarlane EH et al. | 2000 | intact cell/cell culture, PC-12 cells (pheochromocytoma cell line from rat adrenal gland) | magnetic field, 50/60 Hz | 4.35–15.8 µT |
Mevissen M et al. | 1996 | animal, rat/Sprague-Dawley, whole body | magnetic field, 50/60 Hz, co-exposure | 50 µT |
Miyakoshi J et al. | 1994 | intact cell/cell culture, human leukemia cell lines (HL60RG, CCRF-CEM9), GM0637 cells (normal human fibroblast cell line), TAT2SF cells (human Louis-Bar syndrome fibroblast cell line) | magnetic field, 50/60 Hz, also other exposures without EMF | 400 mT |
Miyakoshi J et al. | 1996 | intact cell/cell culture, CHO (Chinese hamster ovary) cells | magnetic field, 50/60 Hz | 5 mT |
Morabito C et al. | 2010 | intact cell/cell culture, PC-12 cells | magnetic field, low frequency, 50/60 Hz | 0.1–1 mT |
Morabito C et al. | 2017 | - | magnetic field, 50/60 Hz | - |
Moraveji M et al. | 2021 | intact cell/cell culture, rat adipose-derived mesenchymal stem cells | magnetic field, 50/60 Hz, signals/pulses, also other exposures without EMF, co-exposure | - |
Moya-Gómez A et al. | 2023 | intact cell/cell culture, BV2 cells (immortalized murine microglial cell line), SHSY5Y cells, (immortalized human neuroblastoma cell line), primary mouse microglia and neurons, animal, mongolian gerbils <i>(Meriones unguiculatus)</i> (stroke model) | 50/60 Hz, magnetic field | - |
Naarala J et al. | 2017 | intact cell/cell culture, human umbilical vein endothelial cells (HUVEC), C6 cells (rat glioma cell line) | static magnetic field, magnetic field, 50/60 Hz, co-exposure, shielding/field deprivation | 0.2–120 µT |
Nafziger J et al. | 1997 | intact cell/cell culture, human bone marrow cells | magnetic field, 50/60 Hz | 10 µT–1 mT |
Naghibzadeh M et al. | 2020 | intact cell/cell culture, human dermal fibroblasts | magnetic field, 50/60 Hz | 1–5 mT |
Nascimento LF et al. | 2003 | bacterium, <i>Escherichia coli</i>/ATCC 25922 | magnetic field, 50/60 Hz | 500 µT |
Nasrabadi N et al. | 2018 | intact cell/cell culture, human retinal pigment epithelial cells | 50/60 Hz, signals/pulses, magnetic field | 1 mT |
Nawrotek P et al. | 2014 | bacterium, <i>Escherichia coli</i>/O157:H7 and E68II/0141 and <i>Staphylococcus aureus</i>/FRI 913, ATCC 25923 and ATCC 43300 | magnetic field, 50/60 Hz | 30 mT |
Nindl G et al. | 1997 | intact cell/cell culture, Jurkat cells (clone E6-1; T-lymphocyte hybridoma cell line) | magnetic field, signals/pulses, 50/60 Hz | 0.1–1.8 mT |
Novak J et al. | 2007 | intact cell/cell culture, yeast (<i>Saccharomyces cerevisiae</i>) | magnetic field, 50/60 Hz | 5.2–10 mT |
Nurković J et al. | 2017 | - | magnetic field, 50/60 Hz, low frequency, also other exposures without EMF, co-exposure | - |
Oladnabi M et al. | 2019 | - | magnetic field, signals/pulses, 50/60 Hz | - |
Oncul S et al. | 2016 | bacterium, <i>Escherichia coli, Staphylococcus aureus</i> | magnetic field, 50/60 Hz | - |
Ozlem-Caliskan S et al. | 2016 | - | magnetic field, 50/60 Hz, signals/pulses | - |
Paile W et al. | 1995 | intact cell/cell culture, human peripheral blood lymphocytes and human peripheral whole blood | magnetic field, signals/pulses, 50/60 Hz, occupational | 30 µT–1 mT |
Pang L et al. | 2002 | intact cell/cell culture, K562 cells (human erythroleukemic cell line) | magnetic field, 50/60 Hz | 4.4–13 mT |
Paradisi S et al. | 1993 | intact cell/cell culture, K562 cells (human erythroleukemic cell line) | magnetic field, 50/60 Hz | 2.5 mT |
Parola AH et al. | 2005 | intact cell/cell culture, embryonic chicken fibroblasts, plant, duckweed (<i>Spirodela oligorrhiza</i>) | magnetic field, 50/60 Hz, co-exposure | 0.7 mT |
This website uses cookies to provide you the best browsing experience. By continuing to use this website you accept our use of cookies.